The novel ,-lactam antibiotics ceftazidime and moxalactam combine a high stability to 1B-lactamases with an enhanced potency against gram-negative species. In studies using clinical isolates of a wide range of species, both antibiotics were very active against all species of Enterobacteriaceae (1, 6, 7, (11) (12) (13) (14) (15) . Moxalactam exhibits moderate antipseudomonal activity, whereas the newly developed ceftazidime has significantly higher activity against Pseudomonas aeruginosa and other Pseudomonas species (7, 13, 14) .
In this study, we compared the pharmacokinetic properties of the two antibiotics after their administration in 1-g doses intravenously (i.v.) and intramuscularly (i.m.) in healthy adult volunteers.
MATERIALS AND METHODS Subjects and study design. Eight healthy male volunteers participated in this study after providing informed consent. They ranged from 22 to 24 years of age and were 72.6 ± 4.8 kg in weight and 1.9 ± 0.1 m2 in surface area; creatinine clearance was 120.5 ± 18.8 ml/min. They had no significant medical history, no allergy to 1-lactam antibiotics, and normal renal and liver function tests.
There were four parts to this study. In the first, each volunteer was given a 1-g dose of moxalactam by i.m. injection into the buttock. In the second, performed at least 7 days later, the subjects were given a 1-g dose of the same antibiotic by the i.v. route through a slow (3 min) bolus injection. In the third part, the same subjects were given a 1-g dose of ceftazidime by the i.m. route, and in the fourth part, at least 1 week later, the same dose was given by the i.v. route.
Subjects fasted overnight and up to 2 h after drug administration in each segment of the study. On the day of drug administration, 400 ml of fluid was given orally in the morning to ensure adequate diuresis, followed by additional volumes to make up for urine eliminated during the 24-h collection periods. Breakfast was allowed 2 h after the antibiotic morning dosing. Ceftazidime (Glaxo Laboratories) as the monosodium salt and moxalactam (Eli Lilly & Co.) in 1-g amounts were dissolved in 3 ml of sterile water for i.m. injections and in 10 ml of water for i.v. injections. Each i.v. dose was injected over a period of 3 min into an antecubital vein. An i.v. cannula with a butterfly needle was inserted into the contralateral arm vein and maintained patent by a minimum flushing dose of heparin-saline solution (100 IU/ml).
Blood and urine collections. After discarding the first 1 to 2 ml, 4-ml samples of blood were collected before drug administration (blank sample) at 0 h (at end of i. 12 , and 12 to 24 h after injection of the antibiotic. The volumes were measured, and 10-ml samples were stored at -20°C until assayed.
Preliminary assays showed that moxalactam was stable for at least 2 weeks in both serum and urine ANTIMICROB. AGENTS CHEMOTHER. samples stored at -20°C. Ceftazidime was also stable in urine for 2 weeks at -20°C; however, in serum, especially at the lower concentrations, there was a small loss (<10%) of activity after 1 week, increasing to 22% after 2 weeks, and 73% after 4 weeks. Therefore, ceftazidime samples were assayed within 48 h, and moxalactam samples were assayed within 1 week.
Antibiotic assay. The concentrations of ceftazidime and moxalactam in serum and in urine were determined by an agar-well diffusion method (11) . Ceftazidime and moxalactam preparations of certified potency were used for standards. These were prepared in final concentrations of 128, 64, 32, 16, 8, 4, 2, 1, 0.5, and 0.25 ,ug/ml in human serum for assay of the serum samples and in phosphate buffer (pH 7.0) for assay of the urine samples. Serum samples were assayed undiluted, whereas urine samples were diluted in phosphate buffer as necessary to obtain concentrations in the range of the standard curves. Each specimen was assayed in duplicate, and its content was calculated according to the regression curves of the appropriate standards. Bacillus subtilis 1904 E in antibiotic medium no. 2 (Oxoid) with 0.3% sodium citrate was used for the bioassay of both ceftazidime and moxalactam in the urine and in serum when the concentrations were in the range of 128 and 8 1Lg/ml. The correlation coefficients of the regression lines varied from r = 0.9998 to r = 0.9984. Ceftazidime levels below 8 ,ug/ml were assayed with the more susceptible Proteus morganii NCTC 235 with a susceptibility range between 8 and 0.12 FLg/ml and correlation coefficients between r = 0.999 and r = 0.9972. Moxalactam serum levels below 8 ,ug/ml were assayed with Escherichia coli 10418 in antibiotic medium no. 1 with a susceptibility range between 8 and 0.25 pg/ml and a correlation coefficient of r = 0.9979. All serum samples of a treatment group (i.m. or i.v.) were assayed on one day and the urine samples on the next day. Pharmacokinetic analysis. The serum level data after i.v. administration were analyzed by the two-compartment open pharmacokinetic model (2, 3) , and the decline in serum concentration for each subject was fitted by a computer program, using the least-squares regression analysis and the method of the residuals to the sum of the two exponentials: Cp' = Ae-7+Be-, where Cp' represents the serum concentration at time t after the dose, where a and a are the first-order rate constants of the fast and the slow disposition processes, respectively, and A and B are the zero-time intercepts of the two components of the biexponential curves. Because the injection time was brief (3 min), no corrections were applied to the data for the period of the i.v. infusion (5) . From the usual equations (2, 3, 5) , the following pharmacokinetic parameters, based upon a two-compartment open model, were calculated: the specific first-order rate constants for distribution into (k12) and out of (k21) the peripheral compartment and for elimination of the drug from the body The results are presented as the mean ± standard deviation. Statistical analyses were performed by using Student's t test for paired observations, since both antibiotics were studied in the same individuals.
RESULTS
Tolerance. Both antibiotics were well tolerated when administered i.v. with no pain or local complications. There was slight transient buttock pain in five of eight subjects for 3 to 5 min after the i.m. injection of ceftazidime. More severe buttock pain, mainly at the site of injection and of 5-to 10-min duration, was reported by six of the eight subjects receiving moxalactam.
Comparative kinetics after i.v. administration. Figures 1 and 2 (MIC90) of 136 P. aeruginosa strains and 565 cephalosporin-resistant Enterobacteriaceae (13) against the serum curves of ceftazidime and moxalactam ( Fig. 1 and 2) . The MIC90 against the Enterobacteriaceae was exceeded by the serum levels of ceftazidime, after a 1,000-mg dose, for about 8 h and by the serum levels of moxalactam for about 10 h. From the clinical viewpoint, this slight difference is probably irrelevant. However, the MIC90 against P. aeruginosa was exceeded by serum levels of ceftazidime for about 6 h and for only 1 h by moxalactam. This difference could make ceftazidime the better choice to start an empiric treatment of patients with severe infection by gram-negative species in environmental circumstances where P. aeruginosa infections may be expected.
